Oligodendrocyte

Type: Keyphrase
Name: Oligodendrocyte
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Characterization of Oligodendroglial Populations in Mouse Demyelinating Disease Using Flow Cytometry: Clues for MS Pathogenesis

by Andrew P. Robinson, Jane M. Rodgers, Gwendolyn E. Goings, Stephen D. MillerCharacterizing and enumerating cells of the oligodendrocyte lineage (OLCs) is crucial for understanding demyelination and therapeutic benefit in models of demyelinating disease ... [Published Plosone.org - 8 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Adult OPC gliomagenesis by multistep reactivation [Genetics]

Rui Pedro Galvao a , Anita Kasina a , Robert S. McNeill b , Jordan E. Harbin c , Oded Foreman d , Roel G. W. Verhaak e , Akiko Nishiyama f , C. Ryan Miller b , g , and Hui Zong a , h , 1 a Institute of Molecular Biology, University of Oregon ... [Published PNAS - 15 hours ago]
First reported Sep 14 2014 - Updated Sep 14 2014 - 1 reports

News from ACTRIMS/ECTRIMS 2014 Pharma in the hunt for remyelination

#MS research Pharma led #remyelination trials ongoing RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY Zhao,AA Liu1, JP Rubio, D Krull, J Lu, M Song, P Thompson,S Wang1, JC Richardson.Histamine H3 receptor negatively regulates oligodendrocyte differentiation ... [Published Multiple Sclerosis Research - Sep 14 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Form: Non-technical summaries granted during 2013: volume 29

The following projects are listed in volume 29 of 2013:regulation of breathing by hypoxia and hypercapnia (covering AMPK, LKB1, pulmonary) functional magnetic resonance imaging in mice (covering fear memory, rodents) cross-talk between signalling intermediates ... [Published HM Treasury - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

ENDECE Neural to Present Updated NDC-1308 Data at ECTRIMS/ACTRIMS Meeting

New Data Show In Vivo Induction of Remyelination in Animal Model of Multiple Sclerosis (MS)MEQUON, Wis.--(BUSINESS WIRE)--September 09, 2014--ENDECE Neural announced today the forthcoming presentation of new, pre-clinical evidence that the company's lead ... [Published Scottrade - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

In the Dock another remyelintion signal

Namekata K, Kimura A, Harada C, Yoshida H, Matsumoto Y, Harada T.  Dock3 protects myelin in the cuprizone model for demyelination. Cell Death Dis. 2014 Aug 28;5:e1395 Dedicator of cytokinesis 3 (Dock3) belongs to an atypical family of the guanine nucleotide ... [Published Multiple Sclerosis Research - Sep 09 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Impaired Eukaryotic Translation Initiation Factor 2B Activity Specifically in Oligodendrocytes Reproduces the Pathology of Vanishing White Matter Disease in Mice

1 , 2 , Xiaosha Pang 1 , 2 , Guangcun Huang 1 , 2 , Stephanie Jamison 1 , 2 , Jingye Fang 1 , 2 , Heather P. Harding 3 , David Ron 3 , and Wensheng Lin 1 , 2 1 Department of Neuroscience, and 2 Institute for Translational Neuroscience, University ... [Published Journal of Neuroscience - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

TACE/ADAM17 Is Essential for Oligodendrocyte Development and CNS Myelination

1 , Howard C. Crawford 2 , Michael Klingener 1 , Bingru Sun 1 , Jason Karelis 1 , Elaine W. Raines 3 , and Adan Aguirre 1 1 Department of Pharmacological Sciences, Centers for Molecular Medicine, Stony Brook University, SUNY, New York 11794, ... [Published Journal of Neuroscience - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex

1 , * , Kenian Chen 2 , 3 , * , Steven A. Sloan 1 , * , Mariko L. Bennett 1 , Anja R. Scholze 1 , Sean O'Keeffe 4 , Hemali P. Phatnani 4 , Paolo Guarnieri 7 , 9 , Christine Caneda 1 , Nadine Ruderisch 5 , Shuyun Deng 2 , 3 , Shane A. Liddelow ... [Published Journal of Neuroscience - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

Asterias Biotherapeutics Begins Next Phase of Cervical SCI Trial

Alameda, Calif.-based BioTime Inc.’s subsidiary Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical ... [Published ODT Mag - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Molecular regulation of hypoxic-ischemic brain damage

Ratings require JavaScript to be enabled.Oligodendrocyte lineage gene 1 (Olig1) plays a key role in hypoxic-ischemic brain damage and myelin repair.After miRNA-9 transfection, noticeable green fluorescence (plasmid with GFP gene, arrow) was found in brain ... [Published Medical News Today - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Principal Scientist: Immunoregulation

Org Marketing StatementAll over the world, Pfizer colleagues are working together to positively impact health for everyone, everywhere. Each position at Pfizer touches and contributes to the success of our business and our world. That’s why, as one of ... [Published PharmaDiversity - Aug 27 2014]

Quotes

Pedro Lichtinger, Asterias' chief executive officer, said: "The Asterias collaboration with Cancer Research UK's Drug Development Office and CRT represents a major step in advancing our proprietary dendritic cell platform for the potential benefit of patients."
"Enhancement of insulin secretion in type II diabetic patients is promoted with drugs such as sulfonylureas, thiazolidinediones (TZD) or GLP-1 receptor agonists, but these treatments do not prevent .beta cell exhaustion. Oral anti-diabetics (insulin sensitizers and secretagogues) are found useful during the first stages of the disease when insulin resistance predominates and an insulin pancreatic reserve is still available. However, as pancreatic impairment progresses, basal insulin level starts to be an essential parameter to control for achieving metabolic control in patients. At a later stage of T2DM progression, only a basal-bolus regimen of insulin is able to maintain homeostasis in most patients. Currently, no treatment can stably restore a physiological profile of insulin secretion, leading to diabetes progression and development of serious complications."

More Content

All (89) | News (51) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Characterization of Oligodendroglial Population... [Published Plosone.org - 8 hours ago]
Adult OPC gliomagenesis by multistep reactivati... [Published PNAS - 15 hours ago]
Cancer Research UK, Cancer Research Technology ... [Published FierceVaccines - Sep 18 2014]
BioTime CEO Dr. Michael D. West to Present at R... [Published Pharmacy Choice - Sep 17 2014]
Patent Issued for Uses of NOGO-A Inhibitors and... [Published 4 Traders - Sep 17 2014]
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
News from ACTRIMS/ECTRIMS 2014 Pharma in the hu... [Published Multiple Sclerosis Research - Sep 14 2014]
Making Peace With My Abnormal Brain [Published WBUR - Sep 12 2014]
Progressive MS Alliance Grant Funding [Published Newswise - Sep 11 2014]
Cancer Research UK, Cancer Research Technology ... [Published RCL Advisors - Sep 11 2014]
Form: Non-technical summaries granted during 20... [Published HM Treasury - Sep 11 2014]
ASTERIAS BIOTHERAPEUTICS : Patent Application T... [Published 4 Traders - Sep 11 2014]
Tsumura : Data on Ischemia Reported by Research... [Published 4 Traders - Sep 10 2014]
BioTime : Asterias Biotherapeutics to Initiate ... [Published 4 Traders - Sep 10 2014]
BioTime CEO Dr. Michael D. West to Present at R... [Published BioPortfolio - Sep 09 2014]
ENDECE Neural to Present Updated NDC-1308 Data ... [Published Scottrade - Sep 09 2014]
Aspartame and Multiple Sclerosis, Bitter Connec... [Published EMax Health - Sep 09 2014]
In the Dock another remyelintion signal [Published Multiple Sclerosis Research - Sep 09 2014]
Remyelination Therapy Promising in Multiple Scl... [Published General Medicine eJournal - Sep 08 2014]
NOGO blockade promotes remyelination [Published Multiple Sclerosis Research - Sep 07 2014]
Potential Therapeutic Benefit of C1-Esterase In... [Published Plosone.org - Sep 05 2014]
In Vitro Modeling of the Neurovascular Environm... [Published Plosone.org - Sep 04 2014]
Asterias Biotherapeutics Announces Record Date ... [Published Street Sweeper - Sep 04 2014]
Impaired Eukaryotic Translation Initiation Fact... [Published Journal of Neuroscience - Sep 03 2014]
An RNA-Sequencing Transcriptome and Splicing Da... [Published Journal of Neuroscience - Sep 03 2014]
TACE/ADAM17 Is Essential for Oligodendrocyte De... [Published Journal of Neuroscience - Sep 03 2014]
Prominin-1 (CD133) Defines Both Stem and Non-St... [Published Plosone.org - Sep 03 2014]
Oxysterol Mixture in Hypercholesterolemia-Relev... [Published Sexual Development - Sep 03 2014]
Asterias Biotherapeutics Begins Next Phase of C... [Published ODT Mag - Sep 02 2014]
Opexa Therapeutics to Present at September Conf... [Published Nasdaq - Sep 02 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest ...
News from ACTRIMS/ECTRIMS 2014 Pharma in the hu... [Published Multiple Sclerosis Research - Sep 14 2014]
#MS research Pharma led #remyelination trials ongoing RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY Zhao,AA Liu1, JP Rubio, D Krull, J Lu, M Song, P Thompson,S Wang1, JC Richardson.Histamine H3 receptor negatively regulates oligodendrocyte differentiation ...
In the Dock another remyelintion signal [Published Multiple Sclerosis Research - Sep 09 2014]
Namekata K, Kimura A, Harada C, Yoshida H, Matsumoto Y, Harada T.  Dock3 protects myelin in the cuprizone model for demyelination. Cell Death Dis. 2014 Aug 28;5:e1395 Dedicator of cytokinesis 3 (Dock3) belongs to an atypical family of the guanine nucleotide ...
NOGO blockade promotes remyelination [Published Multiple Sclerosis Research - Sep 07 2014]
Pourabdolhossein F, Mozafari S, Morvan-Dubois G, Mirnajafi-Zadeh J, Lopez-Juarez A, Pierre-Simons J, Demeneix BA, Javan M.  Nogo Receptor Inhibition Enhances Functional Recovery following Lysolecithin-Induced Demyelination in Mouse Optic Chiasm.  PLoS ...
MOG extracellular domain (p1-125) triggers elev... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
Background: Myelin-specific T cells are implicated in multiple sclerosis (MS) and drive experimental autoimmune encephalomyelitis (EAE). EAE is commonly induced with short peptides, whereas in MS, whole myelin proteins are available for immune response. ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.